News & Updates
Filter by Specialty:
POSEIDON updates boost treatment potential of tremelimumab-durvalumab-CT for mNSCLC
In the updated analysis of the POSEIDON trial presented at ESMO 2022, the combination regimen comprising tremelimumab, durvalumab, and chemotherapy (T+D+CT) used in the first-line setting conferred long-term overall survival (OS) benefit in individuals with metastatic non-small-cell lung cancer (mNSCLC).
POSEIDON updates boost treatment potential of tremelimumab-durvalumab-CT for mNSCLC
04 Oct 2022
ADT suppresses levels of several androgen precursor steroids
In prostate cancer patients, the initiation of androgen deprivation therapy (ADT) lowers the concentrations of 13 circulating steroids, according to a new study.
ADT suppresses levels of several androgen precursor steroids
04 Oct 2022
Why do psoriasis patients report better QoL amid COVID-19?
Patients with psoriasis report improved quality of life under the COVID-19 pandemic despite harsh movement restrictions, a recent study has found. Such an effect, however, may suggest that current tools do not completely capture the negative impacts of harsh lockdowns on patients’ wellbeing.
Why do psoriasis patients report better QoL amid COVID-19?
04 Oct 2022
Add-on apatinib puts brakes on disease progression in advanced TNBC
The addition of apatinib to vinorelbine appears to prolong progression-free survival in patients with advanced triple-negative breast cancer (TNBC) with failed first- or second-line treatment, as shown in the results of a phase II study.
